Palisade Bio secures patent allowance in China for PALI-2108

Published 31/07/2025, 13:52
Palisade Bio secures patent allowance in China for PALI-2108

CARLSBAD, Calif. - Palisade Bio, Inc. (NASDAQ:PALI), a micro-cap biotech company with a market capitalization of $5.08 million, announced Thursday that China’s National Intellectual Property Administration has issued a Notice of Allowance for a patent covering PALI-2108, the company’s phosphodiesterase-4 B/D inhibitor being developed for fibrostenotic Crohn’s disease and ulcerative colitis. According to InvestingPro data, the company maintains a healthy balance sheet with more cash than debt and a strong current ratio of 2.84.

The patent, titled "Gut Microbiota-Activated PDE4 Inhibitor Prodrug," will cover composition of matter claims for PALI-2108 in China with protection extending into 2045, subject to potential extensions related to regulatory approval timelines.

"Strengthening the global intellectual property portfolio around PALI-2108 remains a priority as we continue advancing this first-in-class therapy," said J.D. Finley, Chief Executive Officer of Palisade Bio, according to the press release.

PALI-2108 is currently being evaluated in a Phase 1b/2a clinical trial for the treatment of fibrostenotic Crohn’s disease and ulcerative colitis. The drug is designed to target the terminal ileum and colon specifically.

The company describes PALI-2108 as the first and only PDE4 inhibitor designed with this specific targeting mechanism for these conditions. Inflammatory bowel disease represents a growing market opportunity in China, with industry forecasts approaching $1 billion in total revenues by 2030, according to information provided in the company statement.

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing therapeutics for autoimmune, inflammatory, and fibrotic diseases. The company expects multiple clinical milestones and data readouts in the next 12-18 months.

In other recent news, Palisade Bio announced positive topline results from its Phase 1 studies of PALI-2108, which is being developed to treat fibrostenotic Crohn’s disease and moderate to severe ulcerative colitis. The trials met their primary endpoints, demonstrating safety, tolerability, and favorable pharmacokinetics, with no serious adverse events reported. Additionally, Palisade Bio presented promising preclinical data for PALI-2108 at Digestive Disease Week, highlighting its potential efficacy in treating ulcerative colitis. The study showed that the drug effectively reduced certain inflammatory markers in a mouse model, suggesting it could alleviate symptoms associated with the disease. Furthermore, Palisade Bio has appointed Emil Chuang to its Board of Directors. Dr. Chuang brings extensive experience in drug development, having contributed to the regulatory approvals of treatments for pediatric Crohn’s disease and morbid obesity. These developments mark significant steps forward for Palisade Bio in its ongoing research and leadership strategies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.